BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31235619)

  • 1. Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas.
    Wang X; Waschke BC; Woolaver RA; Chen Z; Zhang G; Piscopio AD; Liu X; Wang JH
    Cancer Immunol Res; 2019 Aug; 7(8):1318-1331. PubMed ID: 31235619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
    Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
    Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.
    Ashizawa T; Iizuka A; Nonomura C; Kondou R; Maeda C; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Katano I; Ito M; Akiyama Y
    Clin Cancer Res; 2017 Jan; 23(1):149-158. PubMed ID: 27458246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
    Basher F; Dhar P; Wang X; Wainwright DA; Zhang B; Sosman J; Ji Z; Wu JD
    J Hematol Oncol; 2020 Jun; 13(1):74. PubMed ID: 32517713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
    Niknam S; Barsoumian HB; Schoenhals JE; Jackson HL; Yanamandra N; Caetano MS; Li A; Younes AI; Cadena A; Cushman TR; Chang JY; Nguyen QN; Gomez DR; Diab A; Heymach JV; Hwu P; Cortez MA; Welsh JW
    Clin Cancer Res; 2018 Nov; 24(22):5735-5743. PubMed ID: 29784675
    [No Abstract]   [Full Text] [Related]  

  • 6. Histone deacetylase inhibition promotes intratumoral CD8
    McCaw TR; Li M; Starenki D; Liu M; Cooper SJ; Arend RC; Forero A; Buchsbaum DJ; Randall TD
    Cancer Immunol Immunother; 2019 Dec; 68(12):2081-2094. PubMed ID: 31720815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma.
    Wang X; Waschke BC; Woolaver RA; Chen SMY; Chen Z; Wang JH
    Protein Cell; 2020 Jul; 11(7):472-482. PubMed ID: 32162275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.
    Zheng H; Zhao W; Yan C; Watson CC; Massengill M; Xie M; Massengill C; Noyes DR; Martinez GV; Afzal R; Chen Z; Ren X; Antonia SJ; Haura EB; Ruffell B; Beg AA
    Clin Cancer Res; 2016 Aug; 22(16):4119-32. PubMed ID: 26964571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
    Kasanen H; Hernberg M; Mäkelä S; Brück O; Juteau S; Kohtamäki L; Ilander M; Mustjoki S; Kreutzman A
    Cancer Immunol Immunother; 2020 May; 69(5):717-730. PubMed ID: 32036449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
    Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
    Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
    Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
    Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
    Palakurthi S; Kuraguchi M; Zacharek SJ; Zudaire E; Huang W; Bonal DM; Liu J; Dhaneshwar A; DePeaux K; Gowaski MR; Bailey D; Regan SN; Ivanova E; Ferrante C; English JM; Khosla A; Beck AH; Rytlewski JA; Sanders C; Laquerre S; Bittinger MA; Kirschmeier PT; Packman K; Janne PA; Moy C; Wong KK; Verona RI; Lorenzi MV
    Cancer Immunol Res; 2019 Sep; 7(9):1457-1471. PubMed ID: 31331945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
    Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
    Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma.
    Wen T; Sun G; Jiang W; He X; Shi Y; Ma F; Liu P
    EBioMedicine; 2023 Jan; 87():104420. PubMed ID: 36592514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I-Deficient Tumors.
    Seo H; Kim BS; Bae EA; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Immunol Res; 2018 Jun; 6(6):685-695. PubMed ID: 29615398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
    Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
    Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketogenic Diet Alters the Epigenetic and Immune Landscape of Prostate Cancer to Overcome Resistance to Immune Checkpoint Blockade Therapy.
    Murphy S; Rahmy S; Gan D; Liu G; Zhu Y; Manyak M; Duong L; He J; Schofield JH; Schafer ZT; Li J; Lu X; Lu X
    Cancer Res; 2024 May; 84(10):1597-1612. PubMed ID: 38588411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.
    Bertrand F; Montfort A; Marcheteau E; Imbert C; Gilhodes J; Filleron T; Rochaix P; Andrieu-Abadie N; Levade T; Meyer N; Colacios C; Ségui B
    Nat Commun; 2017 Dec; 8(1):2256. PubMed ID: 29273790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
    Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
    Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.